{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,14]],"date-time":"2026-07-14T10:56:36Z","timestamp":1784026596958,"version":"3.55.0"},"reference-count":23,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2025,12,15]],"date-time":"2025-12-15T00:00:00Z","timestamp":1765756800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Oncol."],"abstract":"<jats:p>Immune checkpoint inhibitors (ICIs) have revolutionized the treatment of metastatic renal cell carcinoma (RCC), offering significant survival benefits. Their use, however, can come at the expense of severe immune-related adverse events (irAEs) involving the myocardium and nervous system. We report an 86-year-old male with relapsed clear cell RCC (Fuhrman grade 3, pT3aN0M0) who developed concurrent myocarditis and myasthenia gravis (MG) after receiving Pembrolizumab and Axitinib for multifocal mediastinal relapse. Despite early initiation of high-dose IV methylprednisolone within 24 hours, the patient\u2019s condition deteriorated rapidly, resulting in pneumonia, acute kidney injury requiring hemodialysis, and death. This case highlights the fulminant course of ICI-induced myocarditis and MG, underscoring the importance of prompt recognition, immediate initiation of corticosteroids and IV immunoglobulin, and early consideration of second-line immunomodulatory therapies in severe cases.<\/jats:p>","DOI":"10.3389\/fonc.2025.1624369","type":"journal-article","created":{"date-parts":[[2025,12,15]],"date-time":"2025-12-15T06:27:22Z","timestamp":1765780042000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":2,"title":["Case Report: Fatal myocarditis and myasthenia gravis induced by immune checkpoint inhibitors: concurrent dual adverse events in an older adult"],"prefix":"10.3389","volume":"15","author":[{"given":"Omar","family":"Fakhreddine","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wassim","family":"Assaad","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nour","family":"El Meski","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Firas","family":"Kreidieh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Samir","family":"Alam","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maurice","family":"Khoury","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2025,12,15]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"3801","DOI":"10.1038\/s41467-020-17670-y","article-title":"A decade of immune-checkpoint inhibitors in cancer therapy","volume":"11","author":"Robert","year":"2020","journal-title":"Nat Commun"},{"key":"B2","doi-asserted-by":"publisher","first-page":"186","DOI":"10.3390\/immuno4030013","article-title":"Immune checkpoint inhibitors: fundamental mechanisms, current status and future directions","volume":"4","author":"Younis","year":"2024","journal-title":"Immuno"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.3390\/cancers16071440","article-title":"Immune-related adverse events due to cancer immunotherapy: immune mechanisms and clinical manifestations","volume":"16","author":"Casagrande","year":"2024","journal-title":"Cancers (Basel)"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1001\/jamaoncol.2018.3923","article-title":"Fatal toxic effects associated with immune checkpoint inhibitors: a systematic review and meta-analysis","volume":"4","author":"Wang","year":"2018","journal-title":"JAMA Oncol"},{"key":"B5","doi-asserted-by":"publisher","first-page":"e013757","DOI":"10.1161\/JAHA.119.013757","article-title":"Immune checkpoint inhibitor myocarditis: pathophysiological characteristics, diagnosis, and treatment","volume":"9","author":"Palaskas","year":"2020","journal-title":"J Am Heart Assoc"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1007\/s11912-024-01571-0","article-title":"Clinical issue of myasthenia gravis related to immune checkpoint inhibitors","volume":"26","author":"Kaira","year":"2024","journal-title":"Curr Oncol Rep"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1016\/j.jacc.2018.02.037","article-title":"Myocarditis in patients treated with immune checkpoint inhibitors","volume":"71","author":"Mahmood","year":"2018","journal-title":"J Am Coll Cardiol"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2312695","article-title":"Overall survival with adjuvant pembrolizumab in renal-cell carcinoma","volume":"390","author":"Motzer","year":"2024","journal-title":"N Engl J Med"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2024.1255577","article-title":"Efficacy and toxicity of immune checkpoint inhibitor combination therapy for advanced renal cell carcinoma: a systematic review and network meta-analysis","volume":"15","author":"Chen","year":"2024","journal-title":"Front Immunol"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2020.580287","article-title":"Diagnosis and management of immune-related adverse events (irAEs) in cancer immunotherapy","volume":"11","author":"Liu","year":"2020","journal-title":"Front Pharmacol"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.5858\/arpa.2019-0447-OA","article-title":"Histopathologic characterization of myocarditis associated with immune checkpoint inhibitor therapy","volume":"144","author":"Sobol","year":"2020","journal-title":"Arch Pathol Lab Med"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1186\/s12935-021-02407-8","article-title":"Combination therapy with immune checkpoint inhibitors (ICIs): a new frontier","volume":"22","author":"Vafaei","year":"2022","journal-title":"Cancer Cell Int"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1080\/21645515.2025.2512645","article-title":"A review of immune checkpoint inhibitor-associated myocarditis: epidemiology, pathogenesis, and biomarkers","volume":"21","author":"Xu","year":"2025","journal-title":"Hum Vaccin Immunother"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1093\/europace\/euad122.246","article-title":"Immune checkpoint inhibitor myocarditis with complete heart block: a case series","volume":"25","author":"O\u2019Shea","year":"2023","journal-title":"Europace"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1080\/1750743X.2025.2517522","article-title":"Pembrolizumab-induced myocarditis, myositis, and myasthenia gravis overlap syndrome (IM3OS) treated with efgartigimod: case report","volume":"17","author":"Cobelas-Cartagena","year":"2025","journal-title":"Immunotherapy"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.3390\/jcm12247737","article-title":"Immune checkpoint inhibitors-associated myocarditis: diagnosis, treatment and current status on rechallenge","volume":"12","author":"Frascaro","year":"2023","journal-title":"J Clin Med"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaccao.2022.06.008","article-title":"What is the evidence of the diagnostic criteria and screening of immune checkpoint inhibitor-induced myocarditis","volume":"4","author":"Thuny","year":"2022","journal-title":"JACC CardioOncol"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.1634\/theoncologist.2018-0130","article-title":"Immune checkpoint inhibitor-associated myocarditis","volume":"23","author":"Ganatra","year":"2018","journal-title":"Oncologist"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaccas.2025.105139","article-title":"Steroid-refractory immune checkpoint inhibitor-induced myocarditis responsive to mycophenolate and antithymocyte globulin","volume":"30","author":"Wilson","year":"2025","journal-title":"JACC Case Rep"},{"key":"B20","doi-asserted-by":"publisher","first-page":"319","DOI":"10.1186\/s40425-019-0774-y","article-title":"Immune checkpoint inhibitor related myasthenia gravis: single center experience and systematic review of the literature","volume":"7","author":"Safa","year":"2019","journal-title":"J Immunother Cancer"},{"key":"B21","doi-asserted-by":"publisher","first-page":"518","DOI":"10.1007\/s00520-023-07987-x","article-title":"Improved outcomes with early immunosuppression in patients with immune-checkpoint inhibitor-induced myasthenia gravis, myocarditis and myositis: a case series","volume":"31","author":"Weaver","year":"2023","journal-title":"Support Care Cancer"},{"key":"B22","doi-asserted-by":"publisher","first-page":"528","DOI":"10.1007\/s00520-025-09602-7","article-title":"Immune checkpoint inhibitor-related myasthenia gravis, myocarditis and myositis: further insights","volume":"33","author":"Cooksley","year":"2025","journal-title":"Support Care Cancer"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaccao.2025.02.004","article-title":"Rechallenge after severe immune checkpoint inhibitor myocarditis: venturing into the unknown","volume":"7","author":"Bailly","year":"2025","journal-title":"JACC CardioOncol"}],"container-title":["Frontiers in Oncology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2025.1624369\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,12,15]],"date-time":"2025-12-15T06:27:23Z","timestamp":1765780043000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2025.1624369\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,12,15]]},"references-count":23,"alternative-id":["10.3389\/fonc.2025.1624369"],"URL":"https:\/\/doi.org\/10.3389\/fonc.2025.1624369","relation":{},"ISSN":["2234-943X"],"issn-type":[{"value":"2234-943X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,12,15]]},"article-number":"1624369"}}